Physician profile
Eric R Wiedower
NPI 1154633857
$15,219.51
in general payments reported to CMS, 2019-2025
72 companies · $4,203 in 2025
The $4,203 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $583 · 2021: $926 · 2022: $2,072 · 2023: $2,934 · 2024: $3,566 · 2025: $4,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,990 · Long Term Medical Supply Or Device Loan: $1,696 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,989.95 |
| Long Term Medical Supply Or Device Loan | $1,696.38 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,312.25 | 2019-2025 | |
| Janssen Biotech, INC. | $1,296.94 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $1,189.50 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $985.56 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $842.28 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $661.21 | 2019-2025 | Ninlaro, Iclusig |
| Eisai INC. | $539.35 | 2019-2025 | |
| Pfizer INC. | $536.89 | 2019-2025 | |
| Gilead Sciences, INC. | $464.61 | 2021-2025 | Trodelvy |
| Amgen INC. | $415.53 | 2019-2022 | |
| Celgene Corporation | $414.00 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $395.24 | 2019-2025 | Opdualag, Opdivo |
| Beigene USA, INC. | $393.29 | 2020-2025 | Brukinsa |
| Abbvie INC. | $373.72 | 2019-2025 | Venclexta |
| Lilly USA, LLC | $311.18 | 2019-2025 | Jaypirca, Verzenio |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $280.28 | 2019-2023 | Tivdak, Tukysa, Adcetris |
| Rigel Pharmaceuticals, INC. | $261.67 | 2020-2024 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $176.59 | 2022-2025 | |
| Daiichi Sankyo INC. | $161.96 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Adc Therapeutics America, INC. | $157.09 | 2021-2025 | |
| Genentech USA, INC. | $145.99 | 2019-2024 | Lunsumio, Tecentriq, Columvi |
| Astellas Pharma US INC | $143.40 | 2024-2025 | Vyloy, Padcev, Xtandi |
| Jazz Pharmaceuticals INC. | $141.56 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $131.16 | 2020-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $127.58 | 2019-2025 | Libtayo |
| Tersera Therapeutics LLC | $126.69 | 2019-2024 | Xermelo, Zoladex |
| Genzyme Corporation | $125.16 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2021 | |
| Kyowa Kirin, INC. | $122.06 | 2021-2025 | Poteligeo |
| Incyte Corporation | $117.87 | 2019-2025 | Jakafi |
| Legend Biotech USA INC. | $116.87 | 2025 | Carvykti |
| Morphosys, US INC. | $104.88 | 2022-2023 | Monjuvi |
| Tempus Ai, INC | $98.75 | 2024-2025 | Xt Cdx |
| Pharmacyclics LLC, An Abbvie Company | $92.94 | 2021-2022 | |
| Emd Serono, INC. | $73.87 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $73.18 | 2023-2025 | Ultomiris |
| Genmab U.S., INC. | $70.32 | 2023-2025 | Epkinly |
| Sobi, INC | $69.42 | 2022-2024 | |
| G1 Therapeutics, INC. | $69.08 | 2022-2023 | Cosela |
| Array Biopharma INC | $62.07 | 2025 | Mektovi, Tukysa, Braftovi |
| Adaptive Biotechnologies Corporation | $61.63 | 2022-2025 | Clonoseq |
| Exelixis INC. | $60.71 | 2019-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $57.10 | 2023-2024 | Fotivda |
| Pharmaessentia USA Corporation | $55.24 | 2022-2024 | Besremi |
| Beone Medicines USA, INC. | $47.97 | 2025 | Brukinsa |
| Foundation Medicine, INC. | $40.97 | 2020-2023 | |
| Recordati_rare_diseases_inc. | $40.65 | 2023-2024 | Sylvant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.65 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.40 | 2019-2021 | |
| Clovis Oncology, INC. | $31.65 | 2019 | |
| Pharmacosmos Therapeutics INC. | $29.76 | 2023-2024 | Cosela, Monoferric |
| Puma Biotechnology, INC. | $29.60 | 2021-2024 | |
| Amag Pharmaceuticals, INC. | $29.59 | 2019-2021 | |
| Verastem, INC. | $26.78 | 2025 | Avmapki Fakzynja Co-Pack |
| Sumitomo Pharma America, INC. | $26.41 | 2024 | Orgovyx |
| Agios Pharmaceuticals, INC. | $25.51 | 2019-2023 | Pyrukynd |
| Servier Pharmaceuticals LLC | $25.46 | 2021 | |
| Azurity Pharmaceuticals, INC. | $22.00 | 2025 | Danziten |
| Biocompatibles, INC. | $21.47 | 2019 | |
| Syndax Pharmaceuticals, INC. | $20.08 | 2025 | |
| Geron Corporation | $19.78 | 2025 | Rytelo |
| Spectrum Pharmaceuticals INC. | $19.75 | 2025 | Rolvedon |
| Acrotech Biopharma INC. | $16.45 | 2021 | |
| Karyopharm Therapeutics INC. | $16.38 | 2022 | |
| Corcept Therapeutics | $15.79 | 2025 | Korlym |
| Cti Biopharma Corp. | $15.71 | 2022 | |
| Stemline Therapeutics INC. | $15.57 | 2023 | Orserdu |
| Mirati Therapeutics, INC. | $15.37 | 2023 | Krazati |
| Dova Pharmaceuticals | $14.92 | 2021 | |
| Caris Mpi, INC. | $13.52 | 2025 | Mi Cancer Seek |
| Advanced Accelerator Applications | $11.56 | 2019 | |
| Secura Bio, INC. | $9.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wiedower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.